Targeting XPO6 Inhibits Prostate Cancer Progression and Enhances the Suppressive Efficacy of Docetaxel

0
116
Investigators detected the expression level of XPO6 in prostate cancer tissues by immunohistochemistry and analyzed the correlation between clinicopathological characteristics and XPO6 level based on TCGA database.
[Discover Oncology]
Full Article